Vilon

Not FDA approvedBioregulator ResearchLongevity & cellularImmune & gut
5.7

Neutral, BioHarmony verdict

BioHarmony score 5.7 out of 10

Vilon is the Lysine-Glutamic acid (KE) dipeptide from Vladimir Khavinson's bioregulator program, sold for immune restoration and anti-aging. The cell and animal data are real but come entirely from one lab, with zero independent replication and zero registered trials, per the single-source record summarized in Khavinson 2013.

Read full report

What is Vilon?

Vilon is a lab-made dipeptide, just two amino acids, Lysine and Glutamic acid, stuck together. In peptide circles it goes by the shorthand "KE," and it comes out of Vladimir Khavinson's bioregulator program in St. Petersburg. It is marketed for immune restoration and general anti-aging, and the proposed idea is that this tiny peptide slips into cells and interacts directly with your DNA to nudge gene expression, layered on a thymus and immune-restoring action, per Khavinson 2023.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

Safety watch-outs

  • Any active or suspected cancer: do not use
  • immune and neuroendocrine experimentation is unwise there.
  • Pregnancy or breastfeeding: do not use
  • there is no human safety data.
  • Injection-site infection, fever, or systemic reaction (possible contaminated grey-market material): stop immediately and seek care.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for Vilon yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (2)

Attributed viewpoints, separate from primary research.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalNot FDA approved
CompoundingNo FDA-approved U.S. product is identified in the reviewed source set

Vilon is a synthetic dipeptide studied in cell and animal models. The reviewed human and rat thymic-cell study does not establish clinical safety or effectiveness in people.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.